Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Germany’s Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

EMA committee recommends marketing approval of AVT06, Alvotech’s proposed biosimilar to Eylea: Reykjavik, Iceland Tuesday, June 24, 2025, 17:00 Hrs [IST] Alvotech, a global biot ...

Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), according to a subgroup analysis of the PHOTON trial presented at the recent ...

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF ...

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF ...

Intravitreal anti-VEGF agents are linked to a slight increase in the risk for stroke in patients with age-related macular degeneration, but only for about 2 months after the last injection.

About AVT06 (aflibercept) AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and ...